IP Library Granted Patent US 11,649,451
Granted Patent B2
US 11,649,451 · App. 16/629,013 · Granted May 16, 2023

Evolution of bioactive sequence-defined synthetic polymers using DNA-templated polymerization

Inventors: David R. Liu (Lexington, MA); Zhen Chen (Boston, MA); Phillip Andrew Lichtor (Cambridge, MA)
Assignee: President and Fellows of Harvard College
C12N15/1068A61K31/7115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,649,451
App. No.
16/629,013
Granted
May 16, 2023
Kind
B2
Abstract

The present invention provides methods and compositions for performing ordered multi-step syntheses involving modified nucleic acids by nucleic acid-mediated chemistry. This approach is useful for generating sequence-defined highly functionalized nucleic acid polymers. The invention also provides modified nucleic acid polymers that bind to proteins of interest (e.g., PCSK9 and IL-6), which are implicated in human disease.

Claims (56)

1. A modified nucleic acid library comprising one or more tri-oligonucleotides, wherein each of the one or more tri-oligonucleotides comprises one or more modified cytosine (C) residues of (a) and/or one or more modified thymine (T) residues of (b), at the 5′ end of the one or more tri-oligonucleotides:

(a) wherein the one or more modified C residues are of the formula:

 and

(b) wherein the one or more modified T residues are of the formula:

wherein:

each instance of - - - is independently a single, double, or triple bond;

each instance of n is independently 0, 1, 2, 3, 4, 5, or 6;

each instance of is independently a single bond, —O—, —S—, —N(R A )—, —C(═O)—, —C(═O)O—, —C(═O)N(R A )—, —C(═NR A )—, —C(═NR A )O—, —C(═NR A )N(R A )—, —NR A C(═O)—, —NR A C(═O)O—, —NR A C(═O)N(R A )—, —NR A C(═NR A )—, —NR A C(═NR A )O—, —NR A C(═NR A )N(R A )—, —OC(═O)—, —OC(═O)O—, —OC(═O)N(R A )—, —OC(═NR A )—, —OC(═NR A )O—, or —OC(═NR A )N(R A )—, wherein each instance of R A is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group; and

each instance of R is independently unsubstituted C 1-5 alkyl; substituted or unsubstituted C 2-5 alkenyl; substituted or unsubstituted C 2-5 alkynyl; substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic carbocyclyl; substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic heterocyclyl; substituted or unsubstituted, 6- to 11-membered, monocyclic or bicyclic aryl; or substituted or unsubstituted, 5- to 11-membered, monocyclic or bicyclic heteroaryl.

2. A modified nucleic acid library comprising one or more tri-oligonucleotides, wherein each of the one or more tri-oligonucleotides comprises one or more modified cytosine (C) residues of (a) and/or one or more modified thymine (T) residues of (b), at the 5′ end of the one or more tri-oligonucleotides:

(a) wherein the one or more modified C residues are of the formula:

 and

(b) wherein the one or more modified T residues are of the formula:

wherein:

each instance of - - - is independently a single, double, or triple bond;

each instance of n is independently 0, 1, 2, 3, 4, 5, or 6;

each instance of is independently a single bond, —O—, —S—, —N(R A )—, —C(═O)—, —C(═O)O—, —C(═O)N(R A )—, —C(═NR A )—, —C(═NR A )O—, —C(═NR A )N(R A )—, —NR A C(═O)—, —NR A C(═O)O—, —NR A C(═O)N(R A )—, —NR A C(═NR A )—, —NR A C(═NR A )O—, —NR A C(═NR A )N(R A )—, —OC(═O)—, —OC(═O)O—, —OC(═O)N(R A )—, —OC(═NR A )—, —OC(═NR A )O—, or —OC(═NR A )N(R A )—, wherein each instance of R A is independently hydrogen, substituted or unsubstituted C 1-6 alkyl, or a nitrogen protecting group; and

each instance of R is independently

3. The modified nucleic acid library of claim 2 , wherein the modified nucleic acid library comprises one or more of the following modified tri-oligonucleotides:

(a) C 1 TT, C 1 TG, C 1 GT, and C 1 CG, wherein C 1 is

wherein R is

(b) C 2 AA, C 2 AC, C 2 TC, and C 2 GG, wherein C 2 is

wherein R is

(c) C 3 AT, C 3 AG, C 3 GA, and C 3 GC, wherein C 3 is

wherein R is

(d) C 4 TA, C 4 CA, C 4 CT, and C 4 CC, wherein C 4 is

wherein R is

(e) T 1 TT, T 1 TG, T 1 GT, and T 1 CG, wherein T 1 is

wherein R is

(f) T 2 AT, T 2 AG, T 2 GA, and T 2 GC, wherein T 2 is

wherein R is

(g) T 3 AA, T 3 AC, T 3 CA, and T 3 CC, wherein T 3 is

wherein R is

and

(h) T 4 TA, T 4 TC, T 4 CT, and T 4 GG, wherein T 4 is

wherein R is

4. A method of making a modified nucleic acid polymer, the method comprising

(a) contacting two or more nucleic acid molecules from the library of claim 1 with a template nucleic acid, thereby forming a complex, wherein the two or more nucleic acid molecules from the library bind to the template nucleic acid, and

(b) contacting the complex of (a) with a ligase, thereby ligating the two or more nucleic acid molecules from the library to form the modified nucleic acid polymer.

5. A method of making a library of modified nucleic acid polymers, the method comprising

(a) contacting the modified nucleic acid library of claim 1 with a library of template nucleic acids, thereby forming complexes between modified nucleic acids of the modified nucleic acid library and template nucleic acids of the library of template nucleic acids, and

(b) contacting the complexes of (a) with a ligase, thereby forming a library of modified nucleic acid polymers.

6. A method of generating a modified nucleic acid polymer that binds to a target protein comprising

(a) contacting the library of modified nucleic acid polymers made by a method of claim 5 with the target protein, and

(b) isolating one or more nucleic acid polymers that bind to the target protein.

7. The modified nucleic acid library of claim 1 , wherein each instance of - - - is a double bond.

8. The modified nucleic acid library of claim 1 , wherein each instance of n is 0.

9. The modified nucleic acid library of claim 7 , wherein each instance of is independently a single bond or —C(═O)N(R A )—.

10. The modified nucleic acid library of claim 1 , wherein each instance of is independently a single bond or —C(═O)NH—.

11. The modified nucleic acid library of claim 1 , wherein the modified nucleic acid library comprises more than one of the tri-oligonucleotides.

12. The modified nucleic acid library of claim 1 , wherein each of the one or more tri-oligonucleotides comprises one modified C residue of (a) or one modified T residue of (b).

13. The modified nucleic acid library of claim 11 , wherein each of the one or more tri-oligonucleotides comprises one modified C residue of (a) or one modified T residue of (b).

14. The modified nucleic acid library of claim 3 , wherein the modified nucleic acid library comprises the modified tri-oligonucleotides of (a) to (h).

15. The modified nucleic acid library of claim 1 , wherein each instance of n is independently 0, 1, 2, or 3.

16. The modified nucleic acid library of claim 1 , wherein each instance of R is independently unsubstituted C 1-5 alkyl; substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic carbocyclyl; substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic heterocyclyl; substituted or unsubstituted, 6- to 11-membered, monocyclic or bicyclic aryl; or substituted or unsubstituted, 5- to 11-membered, monocyclic or bicyclic heteroaryl.

17. The modified nucleic acid library of claim 1 , wherein each instance of R is independently unsubstituted C 1-5 alkyl; substituted or unsubstituted, 3- to 13-membered, monocyclic or bicyclic carbocyclyl; substituted or unsubstituted, 6- to 11-membered, monocyclic or bicyclic aryl; or substituted or unsubstituted, 5- to 11-membered, monocyclic or bicyclic heteroaryl.

Assignments (4)
CONFIRMATORY LICENSE Recorded Sep 8, 2023
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 064852/0216 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2022
From: CHEN, ZHEN; LICHTOR, PHILLIP ANDREW
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 060907/0840 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2022
From: LIU, DAVID R.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 060907/0850 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 26, 2022
From: HOWARD HUGHES MEDICAL INSTITUTE
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 060907/0853 →
Continuity (3)
Provisional Application 62638901 · Mar 5, 2018
Provisional Application 62529787 · Jul 7, 2017
Related Publication 20200172896A1 · Jun 4, 2020